Document is current
Any future updates will be listed below
-
Authors
Shirouchi, Yuko https://orcid.org/0000-0003-0945-2030
Mishima, Yuko
Fukuhara, Suguru
Makita, Shinichi
Izutsu, Koji
Terui, Yasuhito
Suzuki, Takuro
Kawasaki, Atsuko
Miyake, Takeshi
Maruyama, Dai
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical Co., Ltd (Chugai Pharmaceutical Co., Ltd)
- License Information
-
More Information
Article History
Received: 15 January 2026
Accepted: 20 June 2026
First Online: 2 July 2026
Declarations
:
: Yuko Shirouchi received honoraria from Chugai Pharmaceuticals Ltd. Yuko Mishima has no disclosures. Suguru Fukuhara received honoraria from AbbVie, AstraZeneca, BeOne Medicines, Chugai Pharmaceuticals Ltd, Genmab, Janssen, LOXO Oncology, Mitsubishi Tanabe, Nihon Shinyaku, Ono, and Takeda. Shinichi Makita received honoraria from AbbVie, AstraZeneca, Bristol Meyers Squibb, Chugai Pharmaceuticals Ltd, Genmab, and Gilead Sciences. Koji Izutsu received research funding from AstraZeneca, AbbVie, Incyte, Chugai Pharmaceuticals Ltd, Beigene, Bristol Myers Squibb, Regeneron, Genmab, Novartis, LOXO Oncology, Yakult, Daiichi Sankyo, and Otsuka. Yasuhito Terui received honoraria from Iqvia, Janssen, Nippon Shinyaku, and MR Nintei Center. Takuro Suzuki and Takeshi Miyake are employed at Chugai Pharmaceuticals Ltd and own stock from Chugai Pharmaceuticals Ltd. Atsuko Kawasaki is employed at Chugai Pharmaceuticals Ltd. Dai Maruyama received honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai Pharmaceuticals Ltd, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, Bristol Myers Squib, Genmab, Novartis, and Pfizer, research funding from Ono, Janssen, Eisai, Chugai Pharmaceuticals Ltd, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, Novartis, Otsuka, Taiho, Pfizer, and Astellas, and consultancy from Janssen, AstraZeneca, Chugai Pharmaceuticals Ltd, AbbVie, Genmab, Sanofi, Briston Myers Squibb, and Pfizer.
